title: Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection in mice.
abstract: Despite the protective role that blood brain barrier plays in shielding the brain, it limits the access to the central nervous system (CNS) which most often results in failure of potential therapeutics designed for neurodegenerative disorders. Neurodegenerative diseases such as Spinal Muscular Atrophy (SMA), in which the lower motor neurons are affected, can benefit greatly from introducing the therapeutic agents into the CNS. The purpose of this video is to demonstrate two different injection paradigms to deliver therapeutic materials into neonatal mice soon after birth. One of these methods is injecting directly into cerebral lateral ventricles (Intracerebroventricular) which results in delivery of materials into the CNS through the cerebrospinal fluid. The second method is a temporal vein injection (intravenous) that can introduce different therapeutics into the circulatory system, leading to systemic delivery including the CNS. Widespread transduction of the CNS is achievable if an appropriate viral vector and viral serotype is utilized. Visualization and utilization of the temporal vein for injection is feasible up to postnatal day 6. However, if the delivered material is intended to reach the CNS, these injections should take place while the blood brain barrier is more permeable due to its immature status, preferably prior to postnatal day 2. The fully developed blood brain barrier greatly limits the effectiveness of intravenous delivery. Both delivery systems are simple and effective once the surgical aptitude is achieved. They do not require any extensive surgical devices and can be performed by a single person. However, these techniques are not without challenges. The small size of postnatal day 2 pups and the subsequent small target areas can make the injections difficult to perform and initially challenging to replicate.
authors: Department of Molecular Microbiology and Immunology, Bond Life Sciences Center, University of Missouri, USA.
authors: Jacqueline J
authors: JJ
authors: Glascock
authors: Erkan Y
authors: EY
authors: Osman
authors: Tristan H
authors: TH
authors: Coady
authors: Ferrill F
authors: FF
authors: Rose
authors: Monir
authors: M
authors: Shababi
authors: Christian L
authors: CL
authors: Lorson
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001812:Blood-Brain Barrier / Q000378:metabolism; D007275:Injections, Intravenous / Q000295:instrumentation / Q000379:methods* / Q000662:veterinary*; D007276:Injections, Intraventricular / Q000295:instrumentation / Q000379:methods* / Q000662:veterinary*; D051379:Mice; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*
chemical_list: D004364:Pharmaceutical Preparations